Blood Transfusion Diagnostic Market Revenue To Flourish At A 7% CAGR By 2032

The global blood transfusion diagnostics market size was valued at US$ 4.42 Billion in 2021 and is expected to expand at a compound annual growth rate CAGR of 7% from 2022-2032.

Fact.MR, in its latest business intelligence study, depicts the nuts and bolts of the global Blood Transfusion Diagnostics market. The report presents detailed information regarding the drivers, restraints, opportunities and trends affecting market growth.

Each segment along with its sub-segment is analyzed in terms of value and volume. Further, the report elaborates the market behavior of each vendor operating in the Blood Transfusion Diagnostics market.

Download Sample Copy of This Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=4720

Key findings of the Blood Transfusion Diagnostics market study:

•          Regional breakdown of the Blood Transfusion Diagnostics market based on predefined taxonomy.
•          Innovative manufacturing processes implemented by Blood Transfusion Diagnostics vendors in detail.
•          Region-wise and country-wise fragmentation of the Blood Transfusion Diagnostics market to grasp the revenue, and growth outlook in these areas.
•          Changing preferences among consumers across various regions and countries.
•          Factors (Positive and Negative) impacting the growth of the global Blood Transfusion Diagnostics market.

Key Companies Profiled

• Grifols S.A.
• Bio-Rad Laboratories, Inc.
• Immucor, Inc.
• CSL Ltd.
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd
• QUOTIENT
• Merck KGaA
• DiaSorin S.p.A.

Competitive Landscape

Grifols S.A., Bio-Rad Laboratories, Inc., Immucor, Inc., CSL Ltd., Abbott Laboratories, F. Hoffmann-La Roche Ltd, QUOTIENT, Merck KGaA, and DiaSorin S.p.A. are the leading market players in the global blood transfusion diagnostics market. These market participants are focused on implementing technological breakthroughs in testing procedures. Plasma fractionation is an example of such technological advancement.

• In October 2019, Ortho Clinical Diagnostics declared FDA approval for the usage of Ortho Sera on its VISION analyzer.
• EryPharm entered the market in April 2021 with an advanced technology that can produce red blood cells in large quantities and build innovative blood transfusion sources.
• F. Hoffmann-La Roche Ltd and Bio-Rad Laboratories, Inc. signed a global partnership agreement in March 2021 to provide customers with access to Bio-full Rad's line of InteliQ products and Unity QC data management solutions.

Key Segments Profiled in the Blood Transfusion Diagnostic Industry Survey

• By Product Type :
• Instruments
• Kits & Reagents
• By Application :
• Blood Grouping
• Disease Screening
• Molecular Disease Screening
• Serological Disease Screening
• By End User :
• Hospitals
• Diagnostic Laboratories
• Blood Banks
• Plasma Fractionation Companies
• Others
• By Region :
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Get Full Access of the Complete Report:
https://www.factmr.com/checkout/4720

Queries addressed in the Blood Transfusion Diagnostics market report:

•          Why are the Blood Transfusion Diagnostics market players targeting region for increased product sales?
•          What patented technologies are the players utilizing in the global Blood Transfusion Diagnostics market?
•          Which regions are displaying the fastest growth in the Blood Transfusion Diagnostics market?
•          What are the underlying micro- macroeconomic factors affecting the global Blood Transfusion Diagnostics market?

Why choose Fact.MR?

Reports published by Fact.MR are a result of the combination of our experts and digital technologies. We thrive to provide innovative business solutions to the clients as well as tailor the reports aligning with the clients’ requisites. Our analysts perform comprehensive research to offer ins and outs of the current market situation. Clients across various time zones tend to utilize our 24/7 service availability.